Main Street Group’s Coherus Oncology CHRS Stock Holding History

Main Street Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200	Closed	-$322	–	798
2024 Q2	$322	Hold	200	–	–	﹤0.01%	814
2024 Q1	$480	Buy	+200	New	+$492	﹤0.01%	838

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Main Street Group's CHRS Position: Q3 2024 in Review

Main Street Group sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 200 shares — an estimated $322 sold.

Main Street Group first reported a position in CHRS in Q1 2024 and held it in 2 quarters. The position peaked at $480 in Q1 2024. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

Main Street Group reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
Main Street Group sold 200 Coherus Oncology shares in Q3 2024, an estimated $322.
Main Street Group first reported a position in Coherus Oncology in Q1 2024 and held it in 2 quarters.
Main Street Group's Coherus Oncology position peaked at $480 in Q1 2024.
128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Main Street Group's 13F filing for Q3 2024, filed 13 Nov 2024.